Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Rhys Mant 0121 414 6788
brainmatrix@trials.bham.ac.uk


Joshua Savage j.savage.1@bham.ac.uk


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Tessa Jowell BRAIN MATRIX - Platform Study
Back

Tessa Jowell BRAIN MATRIX - Platform Study

Recruiting

Open to: ALL

Age: 16.0 - N/A

Edinburgh London Cambridge Glasgow Manchester Oxford Leeds Nottingham London Birmingham Liverpool Manchester Newcastle upon Tyne

Medical Conditions

Glioma

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The main aim of the Tessa Jowell BRAIN MATRIX - Platform Study is to more precisely determine the exact type of tumour patients have by developing the essential infrastructure to provide rapid and accurate molecular diagnosis. A large network of clinical hubs across the United Kingdom, with expertise in managing patients with brain tumours, will be developed. Once established this infrastructure will facilitate the rapid introduction of clinical trials testing targeted therapies tailored to the genetic changes of an individual's tumour.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Nov 2020 Mar 2026

Publications

"Watts C, Savage J, Patel A, Mant R, Wykes V, Pohl U, Bulbeck H, Apps J, Sharpe R, Thompson G, Waldman AD, Ansorge O, Billingham L; TJBM Investigators. Protocol for the Tessa Jowell BRAIN MATRIX Platform Study. BMJ Open. 2022 Sep 8;12(9):e067123. doi: 10.1136/bmjopen-2022-067123."; "36378622"

OBSERVATIONAL

Intervention Type : OTHER
Intervention Description : For patient's undergoing surgery fresh tissue will be collected from the initial surgery and frozen until shipment to the Oxford BRAIN MATRIX Lab. Matched blood sample for germline DNA will be taken post-Platform Study entry. For patients with progression with available tumour samples from previous tumour surgery, blood will be collected and sent to Oxford along with their tumour samples.

Samples will be shipped together to Oxford for molecular analysis (Whole Genome Sequencing (WGS) and EPIC array). The BRAIN MATRIX neuropathology and genomics team will produce an integrated report (histology, WGS, Heidelberg Classifier) for each case in consultation with the local neuropathology team. Once data is available, a virtual MDT with the BRAIN MATRIX neuropathology, genomics team and local site will be held to ensure all relevant information is incorporated in the final BRAIN MATRIX diagnostic report. The resulting integrated histological-molecular report will be available to local sites


Intervention Type : OTHER
Intervention Description : Tessa Jowell BRAIN MATRIX centres in England can submit matched tissue and blood samples for Whole Genome Sequencing through the standard of care NHS Genomic Medicine Service pathway via their Genomic Laboratory Hub. For those from Devolved Nations, samples must go to the Oxford BRAIN MATRIX Laboratory who can facilitate the processing of samples through an alternative NHS GMS GLH or via the research pathway.




You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Nhs Lothian
    Edinburgh
    EH4 2XU
  • Charing Cross Hospital, Imperial College Healthcare NHS Trust
    London
    W6 8RF
  • Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust
    Cambridge
    CB2 0QQ
  • Queen Elizabeth Unviersity Hospital, NHS Greater Glasgow and Clyde Health Board
    Glasgow
    G51 4TF
  • The Christie Hospital, The Christie NHS Foundation Trust
    Manchester
    M20 4BX
  • John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust
    Oxford
    OX3 9DU
  • St James's University Hospital, Leeds Teaching Hospitals NHS Trust
    Leeds
    LS9 7TF
  • Queen's Medical Centre, Nottingham University Hospitals NHS Trust
    Nottingham
    NG7 2UH
  • King's College Hospital, King's College Hospital NHS Foundation Trust
    London
    SE5 9RS
  • Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust
    Birmingham
    B15 2TH
  • The Walton Centre, The Walton Centre NHS Foundation Trust
    Liverpool
    L9 7LJ
  • Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust
    Manchester
    M6 8HD
  • Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust
    Newcastle upon Tyne
    NE7 7DN

Joshua Savage j.savage.1@bham.ac.uk


Rhys Mant 0121 414 6788
brainmatrix@trials.bham.ac.uk



The study is sponsored by University of Birmingham and is in collaboration with The Brain Tumour Charity; University of Oxford; University of Edinburgh; Genomics England.



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT04274283
Last updated 09 December 2024

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top